Current Opinion in Oncology最新文献_第2页

Thymic malignancies: role of immunotherapy and novel approaches. 胸腺恶性肿瘤：免疫疗法的作用和新方法。

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-01-01 Epub Date: 2024-09-23 DOI: 10.1097/CCO.0000000000001101

Barbara Kiesewetter, Philipp Melhorn, Thorsten Fuereder

{"title":"Thymic malignancies: role of immunotherapy and novel approaches.","authors":"Barbara Kiesewetter, Philipp Melhorn, Thorsten Fuereder","doi":"10.1097/CCO.0000000000001101","DOIUrl":"10.1097/CCO.0000000000001101","url":null,"abstract":"Purpose of review: Thymic epithelial tumors (TETs) are a diverse group of malignancies that include thymomas (T), thymic carcinomas (TC), and thymic neuroendocrine tumors. Given the rarity of this disease, evidence defining the optimal treatment approach in the advanced/metastatic setting is limited. This article reviews the latest advances in systemic therapy for TETs, with a special focus on immunotherapy and targeted therapy strategies.Recent findings: Multiple recent efforts have been made to integrate novel immunotherapies and targeted therapy approaches into the current treatment algorithm for T and TC. In addition to trials of checkpoint inhibitor monotherapy, combinatorial approaches with novel immunotherapies or targeted therapies are being explored. Molecular profiling may help identify druggable targets, further optimizing outcomes in this population.Summary: Immune checkpoint inhibitor therapy has shown promising activity in TETs patients. However, toxicity in an unselected cohort, particularly in T patients, can be substantial, and therefore it is not recommended outside of clinical trials. Until additional research validates biomarkers to safely select patients for immunotherapy, targeted therapies remain a reasonable second-line option. Contemporary next-generation sequencing panels may be applied to identify druggable targets in the absence of standard treatment.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"84-94"},"PeriodicalIF":2.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142343313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent advances in immunotherapy for small cell lung cancer. 小细胞肺癌免疫疗法的最新进展。

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-01-01 Epub Date: 2024-11-02 DOI: 10.1097/CCO.0000000000001105

Ziyuan Ren, Shijie Shang, Dawei Chen

{"title":"Recent advances in immunotherapy for small cell lung cancer.","authors":"Ziyuan Ren, Shijie Shang, Dawei Chen","doi":"10.1097/CCO.0000000000001105","DOIUrl":"10.1097/CCO.0000000000001105","url":null,"abstract":"Purpose of review: This review aims to provide an overview of recent advances in immunotherapy for small cell lung cancer (SCLC), with a focus on the current status of immune checkpoint inhibitors (ICIs), novel combination strategies, and key biomarkers.Recent findings: The integration of ICIs into standard chemotherapy has established them as the first-line treatment for extensive-stage SCLC (ES-SCLC). The ADRIATIC trial further demonstrated the efficacy of ICI maintenance therapy in limited-stage SCLC. Additionally, combining radiotherapy with ICIs has shown promising synergistic effects, including the abscopal and radscopal effects. Ongoing investigations into the combination of ICIs with targeted therapies, such as antiangiogenic agents and DNA damage response inhibitors, have yielded encouraging preliminary results. Notably, the novel therapeutic agent tarlatamab, the first bispecific DLL3-directed CD3 T-cell engager, has recently received FDA approval for second-line treatment of ES-SCLC. Advances in omics technologies have shed light on the intra-tumor and inter-tumor heterogeneity of SCLC, leading to the identification of new molecular subtypes and biomarkers, thereby paving the way for precision medicine.Summary: Despite the improved outcomes associated with immunotherapy in SCLC, the overall clinical benefit remains modest. Further preclinical and clinical studies are essential to identify optimal treatment regimens and enhance therapeutic efficacy.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"17-26"},"PeriodicalIF":2.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142616411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prophylactic cranial irradiation for small cell lung cancer in the era of immunotherapy and molecular subtypes.

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2024-12-03 DOI: 10.1097/CCO.0000000000001111

Veronika Pozonec, Maria Dorothea Pozonec, Clemens Aigner, Joachim Widder, Kristiina Boettiger, Zsolt Megyesfalvi, Balazs Dome

{"title":"Prophylactic cranial irradiation for small cell lung cancer in the era of immunotherapy and molecular subtypes.","authors":"Veronika Pozonec, Maria Dorothea Pozonec, Clemens Aigner, Joachim Widder, Kristiina Boettiger, Zsolt Megyesfalvi, Balazs Dome","doi":"10.1097/CCO.0000000000001111","DOIUrl":"https://doi.org/10.1097/CCO.0000000000001111","url":null,"abstract":"Purpose of review: Small cell lung cancer (SCLC) is an aggressive disease with a poor prognosis, whereas its metastatic capacity carries a predilection for the brain. Although prophylactic cranial irradiation (PCI) has been used to address this problem, upcoming alternatives might necessitate reflection of its application in SCLC treatment.Recent findings: The addition of immunotherapy to treatment guidelines has provided a new strategy for the management of brain metastases. Complementation of immunotherapy with active MRI surveillance could potentially replace PCI and avoid irradiation-related cognitive side effects. SCLC's molecular profile is heterogeneous, with differential response to treatment modalities between subgroups. Investigation of these variances might be essential to improve therapeutic outcomes in SCLC patients.Summary: The role of PCI in SCLC treatment must be examined in light of immunotherapy. We summarize recent results, bearing SCLC subtypes and therapeutic vulnerabilities in mind, to derive tailored treatment strategies for SCLC patients in future settings.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2024-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142767105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Editorial introductions.

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2024-11-01 Epub Date: 2024-10-10 DOI: 10.1097/CCO.0000000000001095

引用次数: 0

Chimeric antigen receptor adoptive immunotherapy in central nervous system tumors: state of the art on clinical trials, challenges, and emerging strategies to addressing them. 中枢神经系统肿瘤的嵌合抗原受体采纳性免疫疗法：临床试验、挑战和新兴应对策略的最新进展。

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2024-11-01 Epub Date: 2024-07-11 DOI: 10.1097/CCO.0000000000001076

Giada Del Baldo, Andrea Carai, Angela Mastronuzzi

{"title":"Chimeric antigen receptor adoptive immunotherapy in central nervous system tumors: state of the art on clinical trials, challenges, and emerging strategies to addressing them.","authors":"Giada Del Baldo, Andrea Carai, Angela Mastronuzzi","doi":"10.1097/CCO.0000000000001076","DOIUrl":"10.1097/CCO.0000000000001076","url":null,"abstract":"Purpose of review: Central nervous system (CNS) tumors represent a significant unmet medical need due to their enduring burden of high mortality and morbidity. Chimeric antigen receptor (CAR) T-cell therapy emerges as a groundbreaking approach, offering hope for improved treatment outcomes. However, despite its successes in hematological malignancies, its efficacy in solid tumors, including CNS tumors, remains limited. Challenges such as the intricate tumor microenvironment (TME), antigenic heterogeneity, and CAR T-cell exhaustion hinder its effectiveness. This review aims to explore the current landscape of CAR T-cell therapy for CNS tumors, highlighting recent advancements and addressing challenges in achieving therapeutic efficacy.Recent findings: Innovative strategies aim to overcome the barriers posed by the TME and antigen diversity, prevent CAR T-cell exhaustion through engineering approaches and combination therapies with immune checkpoint inhibitors to improving treatment outcomes.Summary: Researchers have been actively working to address these challenges. Moreover, addressing the unique challenges associated with neurotoxicity in CNS tumors requires specialized management strategies. These may include the development of grading systems, monitoring devices, alternative cell platforms and incorporation of suicide genes. Continued research efforts and clinical advancements are paramount to overcoming the existing challenges and realizing the full potential of CAR T-cell therapy in treating CNS tumors.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"545-553"},"PeriodicalIF":2.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11460750/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141579229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Modeling the management of patients with human epidermal growth factor receptor 2-positive breast cancer with liquid biopsy: the future of precision medicine. 利用液体活检建立人类表皮生长因子受体 2 阳性乳腺癌患者管理模型：精准医疗的未来。

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2024-11-01 Epub Date: 2024-07-15 DOI: 10.1097/CCO.0000000000001082

Eleonora Nicolò, Caterina Gianni, Giuseppe Curigliano, Carolina Reduzzi, Massimo Cristofanilli

{"title":"Modeling the management of patients with human epidermal growth factor receptor 2-positive breast cancer with liquid biopsy: the future of precision medicine.","authors":"Eleonora Nicolò, Caterina Gianni, Giuseppe Curigliano, Carolina Reduzzi, Massimo Cristofanilli","doi":"10.1097/CCO.0000000000001082","DOIUrl":"10.1097/CCO.0000000000001082","url":null,"abstract":"Purpose of review: In the evolving landscape of human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) management, liquid biopsy offers unprecedented opportunities for guiding clinical decisions. Here, we review the most recent findings on liquid biopsy applications in HER2-positive BC and its potential role in addressing challenges specific to this BC subtype.Recent findings: Recent studies have highlighted the significance of liquid biopsy analytes, primarily circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), in stratifying patients' prognosis, predicting treatment response, and monitoring tumor evolution in both early and advanced stages of BC. Liquid biopsy holds promise in studying minimal residual disease to detect and potentially treat disease recurrence before it manifests clinically. Additionally, liquid biopsy may have significant implication in the management of brain metastasis, a major challenge in HER2-positive BC, and could redefine parameters for determining HER2 positivity. Combining ctDNA and CTCs is crucial for a comprehensive understanding of HER2-positive tumors, as they provide complementary insights.Summary: Research efforts are needed to address analytical challenges, validate, and broaden the application of liquid biopsy in HER2-positive BC. This effort will ultimately facilitate its integration into clinical practice, optimizing the care of patients with HER2-positive tumors.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"503-513"},"PeriodicalIF":2.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141619600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Novel PET tracers in breast cancer for treatment optimization: clinical utility and future perspectives. 用于乳腺癌治疗优化的新型 PET 示踪剂：临床实用性和未来展望。

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2024-11-01 Epub Date: 2024-06-12 DOI: 10.1097/CCO.0000000000001057

Laura Gilardi, Lighea Simona Airò Farulla, Elena Bonatto, Francesco Ceci

{"title":"Novel PET tracers in breast cancer for treatment optimization: clinical utility and future perspectives.","authors":"Laura Gilardi, Lighea Simona Airò Farulla, Elena Bonatto, Francesco Ceci","doi":"10.1097/CCO.0000000000001057","DOIUrl":"10.1097/CCO.0000000000001057","url":null,"abstract":"Purpose of review: There is a critical need for timely and accurate decisions in breast cancer management. This narrative review aims to clarify the potential role of novel PET tracers in optimizing treatment strategies for different breast cancer subtypes.Recent findings: 2-deoxy-2-[18F]-fluoro-D-glucose PET/computed tomography (FDG PET/CT) has a pivotal role in response assessment in metastatic breast cancer, despite its limitations in certain histological and molecular subtypes. Further PET radiopharmaceuticals have been proposed to address these clinical needing.Summary: FES PET/CT demonstrates its usefulness in assessing ER expression and predicting response to therapy in luminal breast cancer, with implications for treatment optimization and monitoring. In HER2-positive and HER2-low breast cancer, HER2-targeted PET tracers show potential in assessing HER2 status, while their accuracy in predicting response to targeted therapies is still debated. PARP-targeted PET imaging holds potential for selecting patients for PARP inhibitors treatments, particularly in triple-negative breast cancer (TNBC), where imaging tools are crucial due to the absence of specific targets. Immunotherapy and antibody-drug conjugates (ADCs) are emerging treatment options for TNBC, and PET imaging targeting immune checkpoints could aid in treatment selection and response monitoring. The dynamic role of PET/CT imaging in tailoring breast cancer treatments requires further multidisciplinary research to validate the clinical utility of targeted tracers.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"514-520"},"PeriodicalIF":2.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141619601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Endocrine therapy for early breast cancer in the era of oral selective estrogen receptor degraders: challenges and future perspectives. 口服选择性雌激素受体降解剂时代的早期乳腺癌内分泌治疗：挑战与未来展望。

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2024-11-01 Epub Date: 2024-08-12 DOI: 10.1097/CCO.0000000000001085

Liliana Ascione, Grazia Castellano, Giuseppe Curigliano, Paola Zagami

{"title":"Endocrine therapy for early breast cancer in the era of oral selective estrogen receptor degraders: challenges and future perspectives.","authors":"Liliana Ascione, Grazia Castellano, Giuseppe Curigliano, Paola Zagami","doi":"10.1097/CCO.0000000000001085","DOIUrl":"10.1097/CCO.0000000000001085","url":null,"abstract":"Purpose of review: Growth and survival of hormone receptor positive breast cancer cells are dependent on circulating hormones (e.g., estrogen and progesterone). Endocrine therapy improved outcomes in both early and advanced hormone receptor positive breast cancer. These treatments include drugs with different mechanisms of action, namely selective estrogen receptor modulators (SERM), aromatase inhibitors, and selective estrogen receptor degraders (SERDs). SERDs represent estrogen receptor antagonists, favoring its degradation and thus interfering with proliferation genes transcription and activation. Fulvestrant is the first approved SERD, administered intramuscularly for treating advanced breast cancer.Recent findings: Oral SERDs have been tested to overcome the limitation of the intramuscular administration, and to increase SERD bioavailability. Recently, an oral SERD, Elacestrant, has been approved by the Food and Drug Administration (FDA) for patients carrying an ESR1 mutation. In fact, oral SERDs seem to be effective in tumors harboring ESR1 mutations, a well known mechanism of resistance to endocrine therapy (especially aromatase inhibitors).Summary: More recently, oral SERDs have been tested in patients with early hormone receptor positive breast cancer, although their impact on survival and in this curative setting compared to standard endocrine therapy still needs to be elucidated. The best timing and duration of SERD administration and specific biomarkers in (neo)adjuvant setting remain largely unknown.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"465-473"},"PeriodicalIF":2.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11460762/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142153365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Patient-reported outcomes in neuro-oncology. 神经肿瘤学的患者报告结果。

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2024-11-01 Epub Date: 2024-07-10 DOI: 10.1097/CCO.0000000000001078

Josien C C Scheepens, Martin J B Taphoorn, Johan A F Koekkoek

{"title":"Patient-reported outcomes in neuro-oncology.","authors":"Josien C C Scheepens, Martin J B Taphoorn, Johan A F Koekkoek","doi":"10.1097/CCO.0000000000001078","DOIUrl":"10.1097/CCO.0000000000001078","url":null,"abstract":"Purpose of review: To provide up-to-date evidence on patient-reported outcomes (PROs) in neuro-oncology, with a focus on the core constructs of health-related quality of life (HRQoL) and the use of PROs in clinical trials and clinical practice.[Supplemental Digital Content: Video Abstract PROs in Neuro-Oncology.mov].Recent findings: PROs are gaining importance in brain tumor research and medical care. For patients with a brain tumor, core PRO constructs are pain, difficulty communicating, perceived cognition, seizures, symptomatic adverse events, physical functioning and role and social functioning, which are assessed through patient-reported outcome measures (PROMs). Initiatives have been taken to improve the reliability and robustness of PRO data, including standardization of items included in clinical trial protocols (the SPIRIT-PRO extension) and formulation of PRO priority objectives for use in clinical trials (the SISAQOL-Innovative Medicines Initiative). In brain tumor patients with cognitive impairment, caregiver-reported outcomes may complement or replace PROs to increase accuracy. The next key challenge will be to widely implement PROs and apply PRO data in clinical practice to benefit patients with brain tumors.Summary: PROs are clinically relevant endpoints providing information only known by the patient. Standardization of the use of PROs in clinical trials and wide implementation in clinical practice is needed to improve HRQoL of brain tumor patients.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"560-568"},"PeriodicalIF":2.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11460742/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141562899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Controversies on chemotherapy for early HR+/HER2- breast cancer: the role of anthracyclines and dose intensification. 早期 HR+/HER2- 乳腺癌化疗的争议：蒽环类药物和剂量强化的作用。

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2024-11-01 Epub Date: 2024-06-12 DOI: 10.1097/CCO.0000000000001062

Francesca Poggio, Chiara Molinelli, Irene Giannubilo, Matteo Lambertini, Eva Blondeaux

{"title":"Controversies on chemotherapy for early HR+/HER2- breast cancer: the role of anthracyclines and dose intensification.","authors":"Francesca Poggio, Chiara Molinelli, Irene Giannubilo, Matteo Lambertini, Eva Blondeaux","doi":"10.1097/CCO.0000000000001062","DOIUrl":"10.1097/CCO.0000000000001062","url":null,"abstract":"Purpose of review: Use of adjuvant chemotherapy significantly reduces the risk of recurrence and improves overall survival (OS) in patients with early-stage breast cancer. However, few data are available on the efficacy of different adjuvant chemotherapy regimens and schedules in patients with hormone receptor positive/HER2-negative (HR+/HER2-) breast cancer. We aim to summarize the available evidence on the efficacy of adjuvant anthracycline-based chemotherapy and of the dose-dense schedule in this specific patient population. Moreover, current controversies in the management of patients with early-stage HR+/HER2- breast cancer are discussed.Recent findings: Patient-level meta-analysis evaluating the role of the addition of an anthracycline to taxane-based chemotherapy showed that recurrence rate was lower among patients receiving anthracycline-based treatment.Patient-level meta-analysis evaluating the role of different schedules of chemotherapy administration showed that the use of adjuvant dose-dense chemotherapy is associated with significant reduction in breast cancer recurrences and breast cancer mortality. Less evidence is available in the neoadjuvant setting.Summary: For patients with high-risk HR+/HER2- breast cancer, (neo) adjuvant anthracycline and taxane-based chemotherapy, and a dose-dense regimen should still be considered the standard of care. However, in patients with intermediate risk breast cancer candidates to chemotherapy, anthracycline-free regimens could be considered the preferred treatment option.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"495-502"},"PeriodicalIF":2.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141619598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0